Effect of ALA -mediated photodynamic therapy in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on bladder cancer cells

Central European Journal of Urology

Volumn 64, Issue 3, 2011, Pages 175-179

  Szliszka, Ewelina ^a,b   Kawczyk Krupka, Aleksandra ^b,c   Czuba, Zenon P ^a   Sieron, Aleksander ^b,c   Krol, Wojciech ^a  

^a Chair and Department of Microbiology and Immunology   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c Center for Laser Diagnostics and Therapy   (Poland)

Author keywords

Apoptosis; Bladder cancer; Photodynamic therapy; TRAIL

Indexed keywords

EID: 80052408818     PISSN: 20804806     EISSN: 20804873     Source Type: Journal    
DOI: 10.5173/ceju.2011.03.art18     Document Type: Article

References (30)

1. Pass HI: Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 1993; 85: 443-456.
2. Dolmans DE, Fukumura D, Jain RK: Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3: 380-387.
3. Buytaert E, Dewaele M, Agostinis P: Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochem Biophys Acta 2007; 1776: 86-107.
4. French AJ, Datta SN, Allman R, Matthews PN. Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cell-line model. BJU Int 2004; 93: 156-161.
5. Grasso M: Bladder cancer: a major public health issue. Eur Urol 2008; 7: 510-515.
6. Colombel M, Soloway M, Akaza H, et al: Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol 2008; 7: 618-626.
7. Kelly JF, Snell ME: Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol 1976; 115: 150-151.
8. Weidelich R, Beyer W, Knuchel R, et al: Whole bladder photodynamic therapy with 5-aminolevulic acid using a white light source. Urology 2003; 61: 332-337.
9. Almasan A, Ashkenazi A: Apo2L/TRAIL: apoptosis signaling, biology and potential for cancer therapy. Cytokine Growth Factor Rev 2003; 14: 337-348.
10. Lee JY, Huerta-Yepez S, Vega M, et al: The NO TRAIL to YES TRAIL in cancer therapy (review). Int J Oncol 2007; 31: 685-691.
11. Szliszka E, Czuba ZP, Mazur B, Zydowicz G, Krol W: TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. Folia Histochem Cytobiol 2009, 47: 579-585.
12. Duiker EW, Mom CH, Jong S, et al: The clinical trail of TRAIL. Eur J Cancer 2006; 42: 2233-2240.
13. Thorburn A, Behbakht K, Ford H: TRAIL-receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat 2008; 11: 17-24.
14. Kruyt F: TRAIL and cancer therapy. Cancer Lett 2008; 263: 14-25.
15. Zhang L, Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228-227.
16. Mizutani Y, Nakao M, Ogawa O, et al: Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol 2001; 165: 263-270.
17. Shankar S, Srivastava RK: Enhancement oh therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 2004; 7: 139-156.
18. Baierlein SA, Distel L, Sieber L: Combined effect of tumor necrosis factor and ionizing radiation on the induction of apoptosis in 5637 bladder carcinoma cells. Strahlenther Oncol 2006; 182: 467-472.
19. Szliszka E, Majcher A, Domino M, et al: Cytotoxic activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) against bladder cancer cells after using chemotherapeutic drugs. Urol Pol 2007; 60: 138-142.
20. Szliszka E, Gebka J, Bronikowska J, Krol W: Dietary flavones enhance the effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on bladder cancer cells. CEJUrol 2010; 63: 138-143.
21. Szliszka E: Cytotoxic activity of tumor necrosis factor-related apoptosisinducing ligand (TRAIL) against bladder cancer cells after photodynamic therapy pretreatment. Doktoral Thesis 2005; SUM Katowice.
22. Manivasager V, Heng P, Hao J, et al: A study of 5-aminolevulic acid and its methyl ester used in in vitro and in vivo systems of human bladder cancer. Int J Oncol 2003; 22: 313-318.
23. Szliszka E, Czuba ZP, Domino M, et al: Ethanolic extract of propolis (EEP) enhances the apoptosis-inducing potential of TRAIL in cancer cells. Molecules 2009; 14: 738-754.
24. Szliszka E, Czuba ZP, Mazur B, et al: Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells. Int J Mol Sci 2010; 11: 1-13.
25. Szliszka E, Czuba ZP, Mazur B, et al: Chalcones and dihydrochalcones augment TRAIL-mediated apoptosis in prostate cancer cells. Molecules 2010; 15: 5336-5353.
26. Bronikowska J, Szliszka E, Czuba ZP, et al: The combination of TRAIL and isoflavones enhance apoptosis in cancer cells. Molecules 2010; 15: 2000-2015.
27. O'Donnell MA: Advances in the management of superficial bladder cancer. Semin Oncol 2007; 34: 85-97.
28. Fotinos N, Campo MA, Popowycz F, et al: 5-Aminolevulinic acid derivatives in photomedicine: Characteristics, application and perspectives. Photochem Photobiol 2006; 82: 994-115.
29. Wu SM, Ren QG, Zhou MO, et al: Protoporhyrin IX production and its photodynamics effects on glioma cells, neuroblastoma cells and normal cerebellar granule cells in vitro with 5-aminolevulic acid and its hexyl ester. Cancer Lett 2003; 2: 123-131.
30. Granville DJ, Jiang H, McManus BM, et al: Fas ligand and TRAIL augment the effect of photodynamic therapy on the induction of apoptosis in JURKAT cells. Int Immunopharmacol 2001; 1: 1831-1840.